Consensus ‘Interferon therapy for patients with influenza, SARS and COVID19’
https://doi.org/10.33667/2078-5631-2021-7-51-58
Abstract
According to the who, the share of acute respiratory viral infections (амма? and influenza) accounts for about 90–95% of all infectious diseases; in russia, influenza and arvi take up to 40% of the total duration of official disability, which determines the significance of this pathology. At the same time, the primary contact of the overwhelming majority of patients with suspected arvi and influenza occurs with a therapist or general practitioner of polyclinics. The proposed consensus of experts is intended to systematize the known approaches to the diagnosis, treatment and secondary prevention of influenza, acute respiratory viral infections and community-acquired pneumonia for their use at outpatient clinics. The schemes of using interferon therapy for arvi and influenza are considered in detail.
About the Authors
N. D. Yushchuk
Moscow State University of Medicine and Dentistry n.a. A. I. Evdokimov
Russian Federation
Russian Federation
Yushchuk Nikolai D.
Moscow
I. V. Maev
Moscow State University of Medicine and Dentistry n.a. A. I. Evdokimov
Russian Federation
Russian Federation
Maev Igor V.
Moscow
A. L. Vertkin
Moscow State University of Medicine and Dentistry n.a. A. I. Evdokimov
Russian Federation
Russian Federation
Vertkin Arkady L.
Moscow
References
1. ВОЗ. Информационный бюллетень. Грипп. Ноябрь 2019 г. WHO. Newsletter. Flu. November 2019
2. On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2016: state report. Federal Service for Supervision of Consumer Rights Protection and Human Welfare. Moscow: 2017.220 p.
3. Influenza and acute respiratory viral infections: modern rational etiotropic and pathogenetic therapy. Algorithms for providing medical care to patients: method. recommendations. Authors-compilers: Nikiforov V.V. et al. M .: Spetskniga. 2018, 20 p.
4. Influenza in adults. Clinical guidelines of the National Scientific Society of Infectious Diseases, 2014.105 p.
5. Smetanina S. V., Nikiforov V. V., Kolobukhina L. V. New coronavirus infection (COVID 19): etiology, epidemiology, clinical presentation, diagnosis, treatment and prevention. Moscow: Moscow City Health Department, 2020.
6. Sologub T.V., Golobokov G.S., Tsvetkov V.V., Tokin I.I. Interferon gamma in the treatment of influenza and other respiratory viral infections. Medical Council 2015; (7): 54–8.
7. Sologub T. V., Midikari A. S., Agafonov V. N., Suzdaltsev A. A., Tsvetkov V.V. Efficiency and expediency of using recombinant interferon gamma in complex therapy of patients with influenza A(H1N1) pdm09. Epidemiology and infectious diseases. 2017; 22 (2): 58–63. DOI: http://dx.doi.org/10.18821/1560–9529–2017–2–58–63.
8. Don ЕS, Emelyanova AG, Yakovleva NN, Petrova NV, Nikiforova MV, Gorbunov EA, et al. Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model. J Med Virol. 2017; 89 (5): 759–766. DOI: 10.1002/jmv.24717.
9. Shestakova, IV., Ivanova, MR., Ulyanova, YS., Go, A., Shabalkin, PI. Effectiveness of Interferon Gamma for the Treatment of Moderate and Severe Influenza by Neuraminidase Inhibitors: The Results of an Open-Label Randomized Controlled Clinical Trial (Season 2018–2019). J Pulm Med Respir Care. 2020; 2 (1): 01–07.
10. Nikiforov V. V., Sologub T. V., Tokin I. I., 3, Tsvetkov V. V., Erofeeva M. K., Zarubaev V.V. Possibility of using interferon-γ for influenza infection. Epidemiology and infectious diseases. 2015; 20 (3): 11–16.
11. Tokin I. I., Nikiforov V. V., Shabalkin P. I., Pimanchev P. V., Isakova J. A., Tsvetkov V.V. Randomized Controlled Parallel-Design Clinical Study of the Efficacy and Safety of Intranasal Interferon gamma in Treatment of Influenza-Like Infections. International Journal of Biomedicine. 2018; 8 (4): 327–322.
12. Belevsky A. S., Burns S.A., Larceva O.A., Myasnikov A. L., Nadaraya V.M., Talyzin P.A. Efficacy and safety of gamma-interferon in the treatment of community-acquired pneumonia: results of an open randomized trial IN / 100000–317. Medicine 2019; 7 (4): 110–125.
13. Plavinskiy S. L., Shabalkin P.I., Isakova J.A. Budget Impact Analysis on the intranasal form of Interferon-Gamma in the Complex Therapy of Influenza in the Russian Federation. Int. Journal of Pharmaceutical research, 2018, 10 (4): 343–345.
14. Sainz B, Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004 Nov 10; 329 (1): 11–7.
15. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID 19)». Версия 9 (20.09.2020). Interim guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID 19)". Version 9 (09/20/2020).
16. Myasnikov A. L., Burns S.A., Talyzin P.A., Ershov F.I. Use of interferon gamma in patients with moderate COVID 19. Accepted for publication in the Russian Medical Journal, 2021; № 1.
17. Myasnikov A. L., Berns S.A., Zverev K.V., Lartseva O.A., Talyzin P.A. Efficacy of Interferon Gamma in the Prevention of SARS-CoV 2 Infection (COVID 19): Results of a Prospective Controlled Trial. International Journal of Biomedicine 10 (3) (2020) 182–188.
Review
For citations:
Yushchuk N.D., Maev I.V., Vertkin A.L. Consensus ‘Interferon therapy for patients with influenza, SARS and COVID19’. Medical alphabet. 2021;(7):51-58. (In Russ.) https://doi.org/10.33667/2078-5631-2021-7-51-58
Views:
306
Email this article 